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Background: Canine mammary carcinoma is common in female dogs, and its poor
prognosis remains a serious clinical challenge, especially in developing countries. Benzyl
isothiocyanate (BITC) has attracted great interest because of its inhibitory effect against
tumor activity. However, its effect and the underlying mechanisms of action in canine
mammary cancer are not well-understood. Here, we show that BITC suppresses
mammary tumor growth, both in vivo and in vitro, and reveal some of the potential
mechanisms involved.
Methods: The effect of BITC on canine mammary cancer was evaluated on CIPp and
CMT-7364, canine mammary carcinoma lines. The cell lines were treated with BITC and
then subjected to wound healing and invasion assays. Cell cycles and apoptosis were
measured using flow cytometry; TUNEL assay; immunohistochemistry (IHC) for caspase
3, caspase 9, and cyclin D1; hematoxylin and eosin (H&E) staining; and/or quantitative
polymerase chain reaction (qPCR).
Results: BITC showed a strong suppressive effect in both CIPp and CMT-7364 cells by
inhibiting cell growth in vitro; these effects were both dose- and time-dependent. BITC
also inhibited migration and invasion of CIPp and CMT-7364 cells. BITC induced G2
arrest and apoptosis, decreasing tumor growth in nude mice by downregulation of cyclin
B1 and Cdk1 expression.
Conclusion: BITC suppressed both invasion and migration of CIPp and CMT-7364 cells
and induced apoptosis. BITC inhibited canine mammary tumor growth by suppressing
cyclinB1 and Cdk1 expression in nude mice.
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INTRODUCTION
Mammary gland carcinomas are the most common cancers in
women and intact female dogs (1). Breast cancer is a growing
cause of cancer-related deaths among women worldwide,
despite targeted therapy and advanced techniques enabling early
detection of the disease (2). Canine mammary tumors (CMTs)
share similar molecular, epidemiological, and biological features
with breast cancer in humans, and these characteristics have
been proven to be useful in understanding complex molecular
aspects of human tumors (3). There is increasing interest in
immunotherapeutic strategies to treat cancers, such as chimeric
antigen receptor (CAR) T-cell therapy (4) and PDL-1 antibody
drugs (5). The dog is an excellent animal model for testing
these modalities in preclinical studies because of the remarkable
similarities with humans. There is an increasing need for novel
potential antitumor chemical agents to inhibit the growth of
CMT and prolong patient survival.
Benzyl isothiocyanate (BITC) is a member of the
isothiocyanate (ITC) family that occurs naturally in cruciferous
vegetables such as cauliflower and cabbage (6). BITC has been
reported to process strong anticancer properties (7). Many
studies have indicated that BITC prevents cancer via various
chemopreventive pathways, and effects such as the induction of
apoptosis in cancer cells are also involved (8). In vitro studies
have revealed that BITC plays an essential role in preventing
cancer by inhibiting cyclin B1/Cdk1 complex expression, which
results in cell cycle arrest (9). The G2 transition in the cell cycle
requires an active cyclin B1/Cdk1 complex (10). Moreover, BITC
has also been reported to exhibit anticancer effects in vivo via the
inhibition of chemically induced cancer (11).
In the present study, we investigated the effects and
mechanism by which BITC inhibits the proliferation of CMT
cells in vitro. BITC was found to induce apoptosis to suppress
tumor growth in nude mice by downregulating cyclin B1
and Cdk1 expression. This study reveals the effect of BITC
in inhibiting mammary cancer and indicates its potential for
prevention or treatment of mammary cancer in both dogs
and humans.
METHODS
Cell Lines and Cell Culture
The CIPp cell line is a CMT cell line that was kindly provided by
the Graduate School of Agricultural and Life Sciences, University
of Tokyo (12). The CMT-7364 cell line, another CMT cell line,
was isolated and generated in our laboratory (13). Both cell
lines were cultured in DMEM (Gibco #C11995500BT) medium
supplemented with 10% fetal bovine serum (Gibco #16000044)
and incubated under 5% CO2 at 37
◦C.
Reagents, Antibodies, and Mice
Dimethylsulfoxide (DMSO) (#D2650) and BITC (#252492) were
bought from Sigma, and 4,6-diamidino-2-phenylindole (DAPI)
(Invitrogen #D1306) was used at a 1:500 dilution to stain
the nuclei.
The following primary antibodies used were purchased
from Abcam: a rabbit polyclonal antibody against Caspase
3 (#ab13847), a rabbit monoclonal antibody (EPR17060)
against Cyclin B1 (#ab181593), a rabbit monoclonal antibody
(EPR18107) against Caspase 9 (#ab202068), a mouse monoclonal
(7F7AB10) antibody against AIF (#ab110327), a rabbit
monoclonal antibody (EPR165) against Cdk1 (#ab224269),
and a rabbit polyclonal antibody against cytochrome (#ab90529).
Rabbit monoclonal antibody (EPR165) against Cdk1 and rabbit
polyclonal antibody against Caspase 3 (#ab13847) were used at a
1:200 dilution for immunohistochemistry (IHC) with an HRP-
labeled anti-rabbit IgG (#G-21231) (1:500 for IHC) secondary
antibody purchased from Invitrogen. Rabbit polyclonal antibody
against Caspase 3 (#ab13847), rabbit monoclonal antibody
(EPR17060) against Cyclin B1 (#ab181593), rabbit monoclonal
antibody (EPR18107) against Caspase 9 (#ab202068), mouse
monoclonal antibody (7F7AB10) against AIF (#ab110327), and
rabbit polyclonal antibody against cytochrome (#ab90529) were
used at a 1:500 dilution for immunofluorescence. Appropriate
fluorescent secondary antibodies Alexa Fluor 488 (#A-11008 and
#A-31561) and 594 (#A32740), also purchased from Invitrogen,
were used at a 1:500 dilution.
Female BALB/c nude mice, 4–6 weeks old, were purchased
from Beijing Vital River Laboratory Animal Technology and
used for tumor xenografts. All animal procedures were approved
by the Institutional Animal Care and Use Committee of China
Agricultural University (approval number: AW20078102-2) in
accordance with the Chinese guidelines for the care and use of
laboratory animals.
Evaluation of Cell Proliferation
CMT-7364 and CIPp cells were seeded in 96-well plates at
a concentration of 1 × 104 cells per well and incubated for
12 h in 5% CO2 at 37
◦C. Cells were treated with different
concentrations of BITC (6.25, 12.5, 25, and 50µM) dissolved
in solvent (DMSO) or solvent alone as a control. After 12,
24, 36, or 48 h, cell viability was evaluated with Cell Counting
Kit-8 (Solarbio #CK04-500T) according to the manufacturer’s
instructions. The optical density (OD) was measured with a
microplate reader (BioTek Instruments, Inc., USA) at 450 nm.
For the colony formation assay, CMT-7364 and CIPp cells
were grown in six-well plates at 1,000 cells per well, and
then treated with different concentrations of BITC (2.5, 5, and
10µM) or with solvent alone as a control. After 24, 48, or
72 h of treatment, the wells were washed with PBS (Hyclone
#SH30256) and incubated with DMEM supplemented with 10%
FBS. After incubation for 10 days, the cells were washed twice
with PBS and stained with 0.1% (w/v) crystal violet (Solarbio
#G1063). The stained cells were imaged using a bright-field
microscope (Zeiss).
Wound Healing Assay
CMT-7364 and CIPp cells were plated in six-well plates at a
density of 5 × 105 cells per well and grown to confluence. Then,
the monolayer cells were scratched with a 200 µl pipette tip to
create a 0.4-mm-wide wound. Cells were treated with different
concentrations of BITC (2.5, 5, and 10µM) or solvent alone as
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a control in FBS-free DMEM and then incubated at 37◦C for 12,
24, and 36 h. Then, plates were observed and photographed using
a microscope (Olympus Corporation, Japan). The relative areas
of open wounds were analyzed using Image Pro Plus 7 (Media
Cybernetics, Inc., Rockville, MD, USA).
Invasion Assay
Transwell filters (8µm pore size, Corning #3495) were placed in
24-well plates. Then, the CMT-7364 and CIPp cells were seeded
onto the filters at a density of 2,000 cells per chamber in 100 µl
of FBS-free DMEM with different concentrations of BITC (2.5,
5, and 10µM) or solvent alone as a control. The lower chambers
were filled with 500µl of DMEMwith 10% FBS. After incubating
for 24 h at 37◦C, the cells on the top side of the filters were
removed with a tipped swab. The cells that had migrated to the
lower chamber were stained with 0.1% (w/v) crystal violet and
observed using a microscope (Olympus Corporation, Japan).
Flow Cytometry
CIPp cells were seeded in six-well plates at 2 × 105 cells
per well and treated with different concentrations of BITC (0,
0.625, 1.25, 2.5, 5, or 10µM). Cells were detached using 0.25%
trypsin (Gibco #25200072). Cells were collected and washed
with PBS three times and then resuspended in 400 µl of
binding buffer (BD Biosciences #556454). Cell cycle fractions
were determined using PI/RNase staining buffer (BD Biosciences
#550825), and cell apoptosis was analyzed using the Annexin V-
FITC/PI apoptosis detection kit (BD Biosciences #556419). All
samples were collected and analyzed on a FACS Calibur flow
cytometer (BD Biosciences, USA), and data were analyzed with
Flow Jo software (Version 7.6.1, USA).
Mouse Xenografts
Tumor xenografts were established in female 4- to 6-week-
old BALB/c nude mice by subcutaneous injection of 2 × 106
CIPp cells suspended in 100 µl of PBS into the mammary
fat pad. On the seventh day after inoculation, six mice from
each group were administered BITC (20 mg/kg body weight)
or solvent alone (control) daily via intraperitoneal injections.
Tumor growth (tumor length and width) and body weights
were measured every 2 days until the 21st day post-injection.
Mice were humanely euthanized via cervical dislocation under
isoflurane anesthesia, and the tumors were harvested. CIPp
xenograft tumor volumes weremeasured and then fixedwith 10%
(v/v) neutral-buffered formalin (Solarbio #G2161), embedded
in paraffin wax, and sectioned serially at a thickness of
3µm. Tumor volume was calculated using the formula length
× width2/2.
A TUNEL technology kit (Roche Applied Science #APT110)
was used for analysis of the tumor tissue (control and BITC
groups). The paraffin-embedded tissue was pretreated, and
the tissue sections were dewaxed and rehydrated. The tissue
sections were then incubated with proteinase K, fixed with
a paraformaldehyde solution, and permeabilized in a sodium
citrate solution. All samples were labeled with the TUNEL
reaction mixture (TdT enzyme solution and FITC solution).
The tissues were analyzed under a fluorescent microscope
(Olympus Corporation, Japan) using an excitation wavelength
of 530 nm and a detection wavelength of 630 nm. The data were
quantified by ImageJ software (Rasband, W.S., ImageJ, National
Institutes of Health, Bethesda, MD, USA) with the following
macro (14).
For IHC, deparaffinized and rehydrated sections were
subjected to microwave-based antigen retrieval in citrate buffer
(∼0.24% trisodium citrate dihydrate, ∼0.038% citric acid, in
water). The sections were then incubated in hydrogen peroxide
buffer (10% H2O2 in methanol) to mask any background
peroxidase activity followed by treatment with blocking solution
(10% goat serum, 0.3% Triton X-100 in PBS). Sections
were stained with appropriate primary antibodies (Caspase
3, caspase 9, AIF, cytochrome C, Cdk1, and Cyclin B1
antibodies) and secondary antibodies (anti-rabbit HRP, anti-
rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 488, and anti-
rabbit Alexa Fluor 594 antibodies). The signals were developed
with diaminobenzidine buffer, and then the sections were
counter-stained with hematoxylin. Tissue sections were mounted
using cover glass and mounting medium (Neomount; Merck,
1,090,160,100) and imaged using 20× and 40× objectives on
a bright-field microscope (Zeiss). Images were captured with
a digital microscope, and the amounts of Caspase 3/Cyclin
B1–positive cells and total cells per image were automatically
calculated by color using ImageJ software (Rasband, W.S.,
ImageJ, National Institutes of Health, Bethesda, MD, USA).
The ratio between Caspase 3/Cyclin B1–positive cells and
total cells was defined as the percentage of Caspase 3/Cyclin
B1–positive cells.
Total RNAs (some parts of the xenografts that were frozen)
were isolated using TRIzol reagent (Invitrogen #15596018)
according to the manufacturer’s instructions. The RNA was
reverse-transcribed into cDNA using a Revert Aid First Strand
cDNA Synthesis Kit (ThermoFisher #K1622). The primers
used for amplifying Bax and Bcl-2 were designed using
Primer 5.0 software, and the primer sequences are shown in
Table 1. Quantitative polymerase chain reaction (qPCR) was
performed using a 7500 Fast Real-Time PCR System (Applied
Biosystems, USA) with SYBR green. Each sample was subjected
to three repetitions. Results were expressed using the 2−11Ct
comparative method: 11Ct = (target gene Ct of experimental
group – reference gene Ct of experimental group) – (target
gene Ct of control group – reference gene Ct of control group).
Beta-actin was used as the reference gene.
TABLE 1 | Sequences of primers used for quantitative polymerase chain reaction
(qPCR).
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Statistical Analysis
All data are presented as mean or mean ± standard deviation
(mean ± SD) for three independent experiments. We analyzed
the differences in data between BITC treatment and control by
t-tests or two-way ANOVA (Primer GraphPad 5 software, USA).
Differences were considered significant at P < 0.05, <0.01, and
<0.001, denoted by ∗, ∗∗, and ∗ ∗ ∗, respectively.
RESULTS
Cell Proliferation Decreased Significantly
After Treatment With BITC
CIPp cells and CMT-7364 cells were treated with various doses
of BITC. Cell viability decreased with increasing doses of BITC
(Figure 1A). The viability of CIPp and CMT-7364 cells at 24 and
48 h following treatment with 12.5µM of BITC was significantly
decreased compared with that of the control (Figure 1B). At both
time points, a significant decrease in cell viability relative to the
controls was observed. The ability of CIPp cells and CMT-7364
cells to form colonies was evaluated following treatment with 2.5,
5, and 10µM of BITC (Figure 1C). The results of 0.1% (w/v)
crystal violet staining suggested that BITC significantly inhibited
colony formation.
BITC Inhibited Cell Migration and Invasion
The suppressive effect of BITC on cell migration and invasion was
evaluated on both CIPp cells and CMT-7364 cells by subjecting
them to BITC treatment or not. A significantly higher inhibitory
effect was observed in cells treated with 10µM BITC for 12, 24,
and 36 h, compared with that in non-treated cells. The wounds
were almost completely healed (86.09 ± 1.76% in CIPp cells,
71.83 ± 7.38% in CMT-7364, respectively) in the control group,
while the BITC groups showed a decrease in healing to 34.77
± 4.59% in CIPp cells and 3.53 ± 1.01% in CMT-7364 cells
at 36 h post-treatment (Table 2 and Figure 2A). BITC caused a
reduction in the migration of the cells into the wound areas in
both cell lines. Transwell assay results showed that the inhibitory
effect of BITC on the invasion of CIPp cells and CMT-7364
cells was dose-dependent (Figure 2B). Compared with that in
the BITC groups, more cells were seen in the lower chambers in
control groups.
BITC Induced Cell Cycle Arrest at the G2
Phase and Apoptosis
To determine whether BITC inhibits CMT cell proliferation
through the induction of apoptosis, the apoptotic rates were
measured by Annexin V/PI staining. There was an increase
in apoptosis rate in the CIPp cell line after 10µM BITC
FIGURE 1 | (A) Cell viability was analyzed using Cell Counting Kit-8 after 0, 12, 24, 36, and 48 h following benzyl isothiocyanate (BITC) treatment, at various
concentrations, in CIPp cells and CMT7364 cells. (B) Cell viability was detected 24 and 48 h after treatment with 12.5µM BITC and normalized to that of controls.
(C) Colony formation of CIPp cells and CMT7364 cells. Cells were treated with 10, 5, and 2.5µM BITC for 24, 48, and 72 h; this was followed with 0.1% (w/v) crystal
violet staining of attached cells after 10 days. **p < 0.01, ***p < 0.001.
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TABLE 2 | Results of wound healing assay (%).
Cell line Post-treatment (h) Control 2.5µM BITC 5µM BITC 10µM BITC
CMT7364 12 48.70 ± 2.64 26.92 ± 3.71*** 3.69 ± 1.76*** 2.66 ± 2.63***
24 52.99 ± 4.53 45.56 ± 3.87** 23.17 ± 3.3*** 6.67 ± 5.79***
36 71.83 ± 7.38 54.43 ± 1.50** 25.21 ± 7.24*** 3.53 ± 1.01***
CIPp 12 47.43 ± 3.14 11.45 ± 5.44*** 7.92 ± 2.90**** 8.89 ± 5.95***
24 73.8 ± 2.00 49.51 ± 7.16** 24.51 ± 5.42*** 16.56 ± 10.42***
36 86.09 ± 1.76 64.61 ± 2.90*** 52.85 ± 4.11*** 34.77 ± 4.59***
BITC, benzyl isothiocyanate. **p < 0.01, ***p < 0.001.
FIGURE 2 | (A) The migratory ability of CIPp and CMT7364 cells was tested at 12, 24, and 36 h post-treatment. (B) Invasion assay: CIPp and CMT7364 cells were
treated with various concentrations of BITC and stained with 0.1% (w/v) crystal violet after 10 days. Flow cytometry (C,D). (C) Flow cytometric analysis of Annexin
V/PI staining in cells. CIPp cells were treated with 0.62, 1.25, 2.5, 5, or 10µM BITC for 12 h. (D) CIPp cells were collected after 6 and 12 h of treatment, and data
were analyzed. *p < 0.05, **p < 0.01, ***p < 0.001.
treatment for 24 h (Figure 2C), indicating that BITC inhibited
mammary cancer cell viability by inducing apoptosis. Cell cycle
progression was evaluated via flow cytometry in the CIPp cell
line. BITC treatment increased the percentage of cells in the G2
phase in the cell line at 6 and 12 h post-treatment (Figure 2D)
(p < 0.05). Distribution of cells in the G2 phase was dose-
dependent: higher concentrations of BITC enhanced cell cycle
arrest at the G2 phase.
BITC Suppressed CIPp Xenograft Tumor
Growth in vivo
As mentioned above, BITC inhibited CMT cell proliferation
in vitro. Therefore, its ability to suppress tumor growth in
vivo was further investigated. The mice in both control and
BITC groups had similar body weights (Figure 3A) and similar
serum levels of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP), gamma-
glutamyl transpeptidase (GGT), total bilirubin (TBIL), blood
urea nitrogen (BUN), and creatinine (CRE), indicating that there
were no differences in terms of organ damage between the
two groups at 21 days post-xenograft (Supplementary Table 1
and Supplementary Figure 1). However, the tumor volumes and
weights of the control group were significantly higher than those
of the tumors isolated from the BITC group at the end of
the treatment period (Figures 3B,C). Microscopic analysis of
hematoxylin and eosin (H&E)–stained tumor sections revealed
typical tumor histological features. The nuclei were generally
larger than those of normal cells (see red arrow in Figure 3D),
and mitotic figures were found (yellow arrow). Additionally,
there were several apoptotic cells in the BITC group (black
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FIGURE 3 | BITC inhibits CIPp tumor growth in vivo. (A) Mouse body weight ratio throughout the treatment. (B) Tumor volume. (C) Tumor weight at day 21. (D)
hematoxylin and eosin (H&E)–stained tumor tissues (scale bar=50µm). Red arrow: karyomegaly. Yellow arrow: mitosis. Black arrow: apoptosis. (E) The H&E-stained
lung tissues of mice. “Normal” represents the lungs of healthy mice (scale bar= 200µm). Black arrow: lung metastasis. **p < 0.01.
FIGURE 4 | (A) TUNEL staining of tumor tissue (scale bar = 50µm). The apoptotic cells were stained by the TUNEL method representing green fluorescence. (B) AIF
and cytochrome c expressed in tumor tissue. The green fluorescence represents the expression of AIF and cytochrome c. (C) Immunofluorescence images showing
the expression of caspase 3 and caspase 9. The green fluorescence represents the expression of caspase 3, and the red fluorescence represents the expression of
caspase 9. (D) Bax/Bcl-2 mRNA expression in tumor tissue; mRNA levels were measured by quantitative polymerase chain reaction (qPCR). *p < 0.05, ****p < 0.001.
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arrow). We also found metastatic tumors in the lungs of the
control group (displayed black arrow in Figure 3E). Tumor-
induced inflammation was observed in both the BITC and
control groups but not in the lungs of healthy mice.
BITC Induced Tumor Apoptosis in vivo
In this study, tumor tissues from BITC-treated mice showed
a higher level of apoptosis than those of the control group
(Figure 4A). Total RNAwas extracted from the tumor tissue, and
the mRNA levels of Bax and Bcl-2 were evaluated by qPCR: in the
BITC groups, higher expression of Bax and lower expression of
Bcl-2 were observed (Figure 4D). We observed high expression
of caspase 3 (the inactive pro caspase 3 and cleaved caspase 3)
and caspase 9, members of the caspase family of protease enzymes
that play key roles in programmed cell death, including apoptosis
(Figure 4C). AIF and cytochrome c, which are important caspase
factors, were also expressed at high levels during apoptosis
(Figure 4B). These results indicate that BITC induces apoptosis
of tumor cells and suppresses tumor growth in vivo.
BITC Regulated the Expression of Cdk1
and Cyclin B1 in vivo
To further investigate the mechanisms by which BITC suppresses
tumor growth, cell cycle distribution was measured in vitro. The
results showed that more cells were arrested in the G2 phase after
treatment compared with the untreated controls (Figure 2D).
Proteins that regulate cell cycle progression, such as Cdk1 and
cyclin B1, were also observed in vivo. The expression of Cdk1
protein in the BITC groups was lower than in the control groups
(Figure 5A) during apoptosis, and a similar result was observed
in terms of the expression of cyclin B1 (Figures 5B,C). Thus,
BITC reduced cyclin B1 and Cdk1 levels, inducing apoptosis to
suppress tumor growth.
DISCUSSION
In this study, BITC showed significant anti-proliferative effects
in two CMT cell lines (Figure 1A). A recent study reported a
similar effect of BITC on the viability of an oral cancer cell
line (7) and additionally demonstrated that BITC inhibited cell
colony formation in a time- and dose-dependent manner. A
significant difference in the migration and invasion ability of
the two cell lines was observed post–BITC treatment. After the
BITC treatment, MCT-7364, an epithelium-like cell line, was
more sensitive to BITC treatment than CIPp cells according
to the wound healing assay results (Figure 2A); this may be
due to the lack of expression of E-cadherin (15), a gene that
mediates cell-to-cell adhesion and is deficient in MCT-7364
cell lines (13). MCT-7364 is a triple-negative canine mammary
cancer cell line that was established and characterized by Zhang
et al. (13). Tumor tissue was found to be negative for HER-
2 by IHC analysis; in comparison, CIPp is a HER-2–positive
FIGURE 5 | (A) Cdk1 expressed in tumor tissue (scale bar = 50µm). The green fluorescence represents the expression of Cdk1. (B) Immunohistochemistry (IHC)
images (scale bar = 50µm) of tumor tissue expressing caspase 3 and cyclin B1. (C) Images of caspase 3 and cyclin B1 staining (scale bar = 50µm). **p < 0.01,
***p < 0.001.
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canine mammary cancer cell line (12). There are four major
molecular subtypes of breast cancer: luminal A, luminal B,
triple-negative, and HER2-enriched (16). There are differences
between two subtypes of breast cancers: triple-negative canine
mammary cancer cell lines are negative for estrogen receptor
(ER), progesterone receptor (PR), and HER-2, while HER-2
enriched cell lines are generally HER-2–positive and lymph
node–positive (17, 18). Some drugs or chemicals exert anticancer
effects by altering cell cycle progression. In canine mammary
carcinoma, ivermectin induces cell cycle arrest at the G1 phase
(19). BITC can also induce cell cycle arrest but mostly at the G2
phase (8). In order to investigate the effect of BITC on tumor
growth in vivo, tumor cell injection was carried out in nude mice.
A decrease in both weights and volumes of mammary metastases
was observed following BITC treatment. Tumors were observed
in the lungs of the control group but not in those of mice
subjected to BITC treatment. This indicates that BITC inhibits
xenografts and suppresses tumor growth (Figure 3B). Moreover,
high doses of BITC treatment did not produce any changes
in the serological levels of ALT, AST, ALP, GGT, TBIL, BUN,
and CRE, indicating that the administration of BITC did not
cause any unexpected organ damage (Supplementary Table 1
and Supplementary Figure 1). Together, these data indicate that
BITC is a potential natural anticancer agent that is safe to
combine with other therapies for treating mammary cancer
(20). Some recent studies have focused on nanoparticles of
sulforaphane, an extensive ITC, and its anticancer effect has
been confirmed both in vivo and in vitro (21, 22). Those
findings suggest the potential to synthesize BITC nanoparticles
with enhanced anticancer effects to act as a potential tool for
BITC delivery.
This study revealed themechanisms underlying the anticancer
activity of BITC in vivo. TUNEL assay results revealed marked
apoptosis (Figure 4A). During this process, the expression of
apoptosis factors, such as AIF and cytochrome c, was upregulated
(Figure 4B); moreover, the level of Bax expression in the control
group was lower than in the BITC-treated group. However,
in contrast, the expression of Bcl-2, a gene that suppresses
apoptosis (23), was significantly lower in the BITC-treated
group (Figure 4D). The Bcl-2 protein belonging to the Bcl-
2 family, which is a family of proteins regulating apoptosis,
is often overexpressed in many tumors (24). In addition, the
expression of cyclin B1/Cdk1 decreased after BITC treatment
(Figures 5A–C); it is well-known that cell cycle progression
is controlled by various cyclins and cyclin-dependent kinases
(Cdks) (25). The expression of Cdk1 and cyclin B1 is required
for the transition from G2 phase into mitosis (26). Here, the
levels of both cyclin B1 and Cdk1 were reduced. In the present
study, BITC inhibited the migration and invasion of CIPp
and CMT-7364 cells and induced apoptosis. The expression
of Cyclin B1 and CDK1 was reduced in tumors from BITC-
treated mice, which resulted in the suppression of tumor growth.
Therefore, these data reveal that BITC possesses anticancer
activity and therapeutic potential for mammary cancer in both
dogs and humans.
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